Changes in Hong Kong stocks | Livzon Pharmaceuticals (01513) rose nearly 4% in the morning. Recently, the participating company Mao Kids® Doxycycline Oral Paste was approved for listing

The Zhitong Finance App learned that Lizhu Pharmaceutical (01513) rose nearly 4% in the morning. As of press release, it had risen 3.67% to HK$21.46, with a turnover of HK$17.8948 million.

^{According to the news, according to Li Zhu Pharmaceutical's official WeChat account, recently, Mao Kids Life Insurance, a participating company of Lifou Pharmaceuticals, announced that its self-developed Mao Kids® doxycycline oral paste has been officially approved for the market.} This product is the first broad-spectrum antibiotic paste in China. It is suitable for infectious diseases caused by doxycycline sensitive bacteria in dogs and cats.

According to industry data, antibiotics are just what dogs and cats need in outpatient clinics. About 29% of dogs and cats that go to the hospital use antibiotics. Among oral antibiotics in dogs and cats, doxycycline has the highest usage rate, especially in scenarios such as upper respiratory tract infections. The main component of Mao Kids ^{® Doxycycline Oral Paste is doxycycline} monohydrate. The pH value of the aqueous solution is close to neutral, and the risk of esophageal burns is low. This API is self-developed by Lizhu Pharmaceutical and helps to achieve quality control throughout the entire link from raw materials to formulations.